Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Browse the programme, visit the ESMO booth, prepare for an outstanding congress experience!
Accepted abstracts are being published. See them here.
Submit your questions to the experts and get best practice recommendations for improved patient care in this real-time discussion.
On the ESMO Perspectives, Dario Trapani reflects on sustainability in cancer care
The ESMO-MCBS is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Online application is open until 28 September 2021
Take part for free in the leading global meeting on molecular developments for personalised cancer care
We were hoping to be in Paris for the ESMO Congress 2021, but the event will be virtual for the second consecutive year due to the COVID-19 pandemic. However, this annual Congress will confirm that cancer research is blooming again, despite the current health crisis and its remarkable consequences on people, healthcare system, and, not the least, research
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care
Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20
Findings from a large, multicentre, retrospective cohort of patients with advanced cancer
An increased risk of sudden or cardiac death
The results from the SAFRON II study of single-fraction versus multifraction stereotactic ablative body radiotherapy
MASCC Survivorship Study Group points to evidence availability for telemedicine interventions only in addressing the psychosocial and physical effects of cancer
The results of the MAST study
Findings from a prespecified exploratory analysis of the OlympiAD study
During this period most of oropharyngeal cancers will be among older non vaccinated individuals
An attempt to unify terminology for future reports and clinical studies in patients with advanced non-small cell lung cancer
New research [to be] presented at the ESMO Congress 2021 suggests that adequate communication and support for children of cancer patients still represents a significant unmet need that parents require help to fulfil.
ESMO launches International Cancer Foundation to make the best cancer care accessible to patients worldwide
The ESMO Congress 2021 will be held as a virtual meeting, on 16-21 September 2021.
Doctors and patients are being advised to reduce unnecessary antibiotic use following new data suggesting that these medicines may increase the risk of cancer of the large intestine (colon), especially in people under 50 years
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021
Test can detect over 50 types of cancer, often before symptoms show
The 2021 World Congress on Gastrointestinal Cancer will be held as a virtual meeting.
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
ESMO has announced today the winners of the 2021 Society Awards.
Record Impact Factor increases for ESMO journals
ESMO Congress 2021: an enhanced virtual experience
Timely presentations of trial data will accelerate transition from research to practice
ESMO is pleased to offer members the opportunity to make a more active contribution to the development of the Society as we are looking to fill an important editorial position in one of our journals and for membership of two of our Working Groups.
Decide is the Health Decision Hub hosted by the World Health Organisation
ESMO has announced a collaboration with the WHO’s International Agency for Research on Cancer (IARC) to support them in the development of an online learning platform which integrates all research for cancer prevention in one easy-to-access point.
ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20
Findings from a large, multicentre, retrospective cohort of patients with advanced cancer
An increased risk of sudden or cardiac death
The results from the SAFRON II study of single-fraction versus multifraction stereotactic ablative body radiotherapy
MASCC Survivorship Study Group points to evidence availability for telemedicine interventions only in addressing the psychosocial and physical effects of cancer
New research [to be] presented at the ESMO Congress 2021 suggests that adequate communication and support for children of cancer patients still represents a significant unmet need that parents require help to fulfil.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
